FAKTOR-OPTIONSSCHEIN - GILEAD SCIENCES | Market Closed - Börse Stuttgart 20:03:07 14/06/2024 BST | ||
| 3.81 EUR | +8.86% |
|
| Current month | +8.86% | ||
| 1 month | -9.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 3.81 | +8.86% |
| 13/06/24 | 3.5 | -1.69% |
| 12/06/24 | 3.56 | -2.47% |
| 11/06/24 | 3.65 | -0.27% |
| 10/06/24 | 3.66 | -0.27% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 08:03 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | Morgan Stanley |
| WKN | MC2VP5 |
| ISIN | DE000MC2VP59 |
| Date issued | 25/07/2019 |
| Strike | 42.02 $ |
| Maturity | Unlimited |
| Parity | 5.67 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 19.21 € |
|---|---|
| Lowest since issue | 3.32 € |
| Spread | 0.01 € |
| Spread % | 0.26% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.06
USD
Average target price
82.7
USD
Spread / Average Target
+27.11%
- Stock Market
- Certificates
- Certificat